Tenofovir alafenamide, usually shortened to TAF, delivers exactly the same active molecule as the older tenofovir disoproxil. What differs is how it gets there, and that difference is the entire point of the drug.
What kind of drug is it?
A nucleotide reverse transcriptase inhibitor, and a prodrug. Like the older form it is inactive as swallowed and must be converted inside the body. It was designed specifically to reduce the kidney and bone effects associated with its predecessor.
How does it work against HIV?
Once converted to tenofovir diphosphate, it resembles a natural DNA building block closely enough that HIV's reverse transcriptase enzyme incorporates it while copying the viral genome. Because it lacks the attachment point for the next building block, the chain terminates and replication fails.
How is it different from tenofovir disoproxil?
It is considerably more stable in the bloodstream. The older form breaks down to tenofovir in plasma, so a large dose is needed and a lot of tenofovir circulates. Alafenamide survives intact until it enters cells, where it is converted, so a much smaller dose achieves higher concentrations inside the cells that matter.
Why does that matter clinically?
Because the kidney and bone effects of tenofovir relate to how much circulates in the blood rather than how much is inside the target cells. Delivering more where it is needed and less everywhere else reduces those effects without reducing the antiviral activity.
What is it used for?
Primarily HIV treatment, as part of combination therapy. Also chronic hepatitis B, against which tenofovir is effective. In some countries it is licensed with emtricitabine for PrEP; in the UK, tenofovir disoproxil with emtricitabine remains standard PrEP, with alafenamide-based prevention used in specific circumstances.
Why is it not standard UK PrEP?
Partly cost, since the older form is available generically and is very cheap, and partly evidence: the main prevention study of alafenamide did not include cisgender women, so conclusions for vaginal sex are limited. For most people the older form works well and is monitored appropriately.
Is one better than the other?
Neither, in general. Alafenamide is easier on kidneys and bones; disoproxil is better for cholesterol and weight and is far cheaper. The right choice depends on your kidney function, bone health, cardiovascular risk and what a regimen needs to achieve.
Is it used on its own?
Rarely. It is almost always part of a combination tablet containing two or three other drugs, because HIV treatment requires more than one active agent to prevent resistance emerging. It is also available paired with emtricitabine alone.
Does it work against hepatitis B?
Yes, and this matters practically. Anyone starting it is tested for hepatitis B first, because stopping abruptly in someone with chronic infection can cause a serious flare of liver inflammation. Where both infections are present, this is factored into the regimen.
How new is it?
It reached clinical use in the mid-2010s and is now a component of several widely used single-tablet regimens. There is well over a decade of clinical experience with it, so it is newer than the older tenofovir rather than genuinely novel.
Who typically takes it?
People on modern single-tablet HIV regimens, particularly those containing bictegravir or a boosted protease inhibitor. Also people with reduced kidney function or bone disease for whom the older tenofovir is unsuitable, and people with chronic hepatitis B.
Does it prevent anything else?
No. Like the older form it covers HIV and hepatitis B only. Everything else transmitted sexually is unaffected, which is why regular screening at every site remains necessary regardless of what you are taking.
Where does it sit against the alternatives?
No antiretroviral is best in every situation. What matters is the fit between the drug and your kidney function, your other medicines, your hepatitis status, your resistance history and how you actually live. That is a conversation with a clinician rather than a ranking.